Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions
Neonatal sepsis is a major cause of infant mortality in developing countries because of delayed injectable treatment, making it urgent to develop noninjectable formulations that can reduce treatment delays in resource-limited settings. Ceftriaxone, available only for injection, needs absorption enha...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Microbiology
2018
|
| _version_ | 1797062373404573696 |
|---|---|
| author | Ba, B Gaudin, K Désiré, A Phoeung, T Langlois, M Behl, C Unowsky, J Patel, I Malick, A Gomes, M White, N Kauss, T |
| author_facet | Ba, B Gaudin, K Désiré, A Phoeung, T Langlois, M Behl, C Unowsky, J Patel, I Malick, A Gomes, M White, N Kauss, T |
| author_sort | Ba, B |
| collection | OXFORD |
| description | Neonatal sepsis is a major cause of infant mortality in developing countries because of delayed injectable treatment, making it urgent to develop noninjectable formulations that can reduce treatment delays in resource-limited settings. Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration. This article presents all available data on the nonparenteral absorption of ceftriaxone in humans and animals, including unpublished work carried out by F. Hoffmann-La Roche (Roche) in the 1980s and new data from preclinical studies with rabbits, and discusses the importance of these data for the development of noninjectable formulations for noninvasive treatment. The combined results indicate that the rectal absorption of ceftriaxone is feasible and likely to lead to a bioavailable formulation that can reduce treatment delays in neonatal sepsis. A bile salt, chenodeoxycholate sodium salt (Na-CDC), used as an absorption enhancer at a 125-mg dose, together with a 500-mg dose of ceftriaxone provided 24% rectal absorption of ceftriaxone and a maximal plasma concentration of 21 µg/ml with good tolerance in human subjects. The rabbit model developed can also be used to screen for the bioavailability of other formulations before assessment in humans. |
| first_indexed | 2024-03-06T20:44:37Z |
| format | Journal article |
| id | oxford-uuid:3571f63a-8fbb-49ea-9769-9f1b3e17c3ae |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:44:37Z |
| publishDate | 2018 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:3571f63a-8fbb-49ea-9769-9f1b3e17c3ae2022-03-26T13:32:01ZCeftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable SolutionsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3571f63a-8fbb-49ea-9769-9f1b3e17c3aeEnglishSymplectic Elements at OxfordAmerican Society for Microbiology2018Ba, BGaudin, KDésiré, APhoeung, TLanglois, MBehl, CUnowsky, JPatel, IMalick, AGomes, MWhite, NKauss, TNeonatal sepsis is a major cause of infant mortality in developing countries because of delayed injectable treatment, making it urgent to develop noninjectable formulations that can reduce treatment delays in resource-limited settings. Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration. This article presents all available data on the nonparenteral absorption of ceftriaxone in humans and animals, including unpublished work carried out by F. Hoffmann-La Roche (Roche) in the 1980s and new data from preclinical studies with rabbits, and discusses the importance of these data for the development of noninjectable formulations for noninvasive treatment. The combined results indicate that the rectal absorption of ceftriaxone is feasible and likely to lead to a bioavailable formulation that can reduce treatment delays in neonatal sepsis. A bile salt, chenodeoxycholate sodium salt (Na-CDC), used as an absorption enhancer at a 125-mg dose, together with a 500-mg dose of ceftriaxone provided 24% rectal absorption of ceftriaxone and a maximal plasma concentration of 21 µg/ml with good tolerance in human subjects. The rabbit model developed can also be used to screen for the bioavailability of other formulations before assessment in humans. |
| spellingShingle | Ba, B Gaudin, K Désiré, A Phoeung, T Langlois, M Behl, C Unowsky, J Patel, I Malick, A Gomes, M White, N Kauss, T Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions |
| title | Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions |
| title_full | Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions |
| title_fullStr | Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions |
| title_full_unstemmed | Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions |
| title_short | Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions |
| title_sort | ceftriaxone absorption enhancement for noninvasive administration as an alternative to injectable solutions |
| work_keys_str_mv | AT bab ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT gaudink ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT desirea ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT phoeungt ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT langloism ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT behlc ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT unowskyj ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT pateli ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT malicka ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT gomesm ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT whiten ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions AT kausst ceftriaxoneabsorptionenhancementfornoninvasiveadministrationasanalternativetoinjectablesolutions |